Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) --  Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes subgroup analyses as poster presentations at the 2024 American College of Cardiology’s Annual Scientific Session (ACC.24) in Atlanta, Georgia. Additionally, the Company will participate in a moderated session in partnership with UT Southwestern Medical Center, host an industry expert theatre, and have a commercial and medical information booth during ACC.24.

"Esperion welcomes the opportunity to showcase additional data from our pivotal CLEAR Outcomes trial at the American College of Cardiology's Annual Scientific Session," said JoAnne Foody, MD, Chief Medical Officer for Esperion. "Complementing the ACC.24 theme of Cardiovascular Care for All, we will highlight our commitment to underserved populations and present subset analyses in women and Hispanic/Latinx patients as well as in patients with obesity."

CLEAR Outcomes Sub-group Poster Presentations

Title:	Characteristics and Outcomes for Statin-Intolerant Women Receiving Bempedoic Acid in the CLEAR Outcomes Trial
Session:	1213
Location:	Hall B4-5
Date & Time:	4/6/24, 9:45 – 10:30 AM ET
Speaker:	Leslie Cho, MD; Cleveland Clinic, Cleveland, Ohio
Title:	Characteristics and Outcomes for Statin-Intolerant Hispanic/Latinx Patients Receiving Bempedoic Acid; Results from a CLEAR Outcomes Pre-Specified Sub-Analysis
Session:	1294
Location:	Hall B4-5
Date & Time:	4/6/24,1:45 – 2:30 PM ET
Speaker:	Fatima Rodriguez, MD, MPH; Stanford Cardiovascular Institute, Stanford Medicine, Stanford, California
Title:	Bempedoic Acid and Cardiovascular Disease Outcomes in Patients with Obesity: A CLEAR Outcomes Subset Analysis
Session: